Mouse Protein NOV homolog(NOV) ELISA kit

Code CSB-EL015956MO
Size 96T,5×96T,10×96T
Trial Size 24T ELISA Kit Trial Size (Only USD$150/ kit)
* The sample kit cost can be deducted from your subsequent orders of 96T full size kits of the same analyte at 1/5 per kit, until depleted in 6 months. Apply now
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Target Name
nephroblastoma overexpressed gene
Alternative Names
Ccn3 ELISA Kit; NovCCN family member 3 ELISA Kit; Cellular communication network factor 3 ELISA Kit; Nephroblastoma-overexpressed gene protein homolog ELISA Kit; Protein NOV homolog ELISA Kit; NovH ELISA Kit
Uniprot No.
Mus musculus (Mouse)
Sample Types
serum, plasma, tissue homogenates
Detection Range
23.5 pg/mL-1500 pg/mL
5.85 pg/mL
Assay Time
Sample Volume
Detection Wavelength
450 nm
Research Area
Assay Principle
Intra-assay Precision (Precision within an assay): CV%<8%
Three samples of known concentration were tested twenty times on one plate to assess.
Inter-assay Precision (Precision between assays): CV%<10%
Three samples of known concentration were tested in twenty assays to assess.
To assess the linearity of the assay, samples were spiked with high concentrations of mouse NOV in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.
  Sample Serum(n=4)
1:1000 Average % 87
Range % 82-91
1:2000 Average % 96
Range % 92-100
1:4000 Average % 91
Range % 86-95
1:8000 Average % 104
Range % 100-112
The recovery of mouse NOV spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.
Sample Type Average % Recovery Range
Serum (n=5) 92 88-96
EDTA plasma (n=4) 84 80-88
Typical Data
These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.
pg/ml OD1 OD2 Average Corrected
1500 2.737 2.623 2.680 2.590
750 1.841 1.715 1.778 1.688
375 1.060 1.004 1.032 0.942
187.5 0.683 0.650 0.667 0.577
94 0.363 0.371 0.367 0.277
47 0.244 0.259 0.252 0.162
23.5 0.171 0.162 0.167 0.077
0 0.093 0.087 0.090  
and FAQs
Store at 2-8°C. Please refer to protocol.
Lead Time
3-5 working days after you place the order, and it takes another 3-5 days for delivery via DHL or FedEx

This Mouse NOV ELISA Kit was designed for the quantitative measurement of Mouse NOV protein in serum, plasma, tissue homogenates. It is a Sandwich ELISA kit, its detection range is 23.5 pg/mL-1500 pg/mL and the sensitivity is 5.85 pg/mL.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

(From Uniprot)
Immediate-early protein playing a role in various cellular processes including proliferation, adhesion, migration, differentiation and survival. Acts by binding to integrins or membrane receptors such as NOTCH1. Essential regulator of hematopoietic stem and progenitor cell function. Inhibits myogenic differentiation through the activation of Notch-signaling pathway. Inhibits vascular smooth muscle cells proliferation by increasing expression of cell-cycle regulators such as CDKN2B or CDKN1A independently of TGFB1 signaling. Ligand of integrins ITGAV:ITGB3 and ITGA5:ITGB1, acts directly upon endothelial cells to stimulate pro-angiogenic activities and induces angiogenesis. In endothelial cells, supports cell adhesion, induces directed cell migration (chemotaxis) and promotes cell survival. Plays also a role in cutaneous wound healing acting as integrin receptor ligand. Supports skin fibroblast adhesion through ITGA5:ITGB1 and ITGA6:ITGB1 and induces fibroblast chemotaxis through ITGAV:ITGB5. Seems to enhance bFGF-induced DNA synthesis in fibroblasts. Involved in bone regeneration as a negative regulator. Enhances the articular chondrocytic phenotype, whereas it repressed the one representing endochondral ossification. Impairs pancreatic beta-cell function, inhibits beta-cell proliferation and insulin secretion. Plays a role as negative regulator of endothelial pro-inflammatory activation reducing monocyte adhesion, its anti-inflammatory effects occur secondary to the inhibition of NF-kappaB signaling pathway. Contributes to the control and coordination of inflammatory processes in atherosclerosis. Attenuates inflammatory pain through regulation of IL1B- and TNF-induced MMP9, MMP2 and CCL2 expression. Inhibits MMP9 expression through ITGB1 engagement.
Gene References into Functions
  1. Taken together, our results suggest that palmitoylation by ZDHHC22 at C241 in the CCN3 TSP1 domain may be required for the secretion of CCN3. Aberrant palmitoylation induces intracellular accumulation of CCN3, inhibiting neuronal axon growth. PMID: 29287726
  2. Administration of EET alters Wnt1, NOV, and HO-1 signaling to prevent obesity-induced cardiomyopathy in obese mice. PMID: 28576832
  3. results show that NOV is a new adipocytokine that could be involved in obesity-associated insulin-resistance. PMID: 27284105
  4. Genetic and pharmacological approaches implicated the ERK1/2 pathway as a critical regulator of CCN3-dependent AAA development. PMID: 26974158
  5. Reduced NOV expression limits inflammation and interstitial renal fibrosis after obstructive nephropathy in mice. PMID: 26367310
  6. NOV is required for the maintenance of articular cartilage and for joint homeostasis, with disruption of NOV in ageing Nov(del3)-/- male mice causing osteoarthritis-like disease. PMID: 25541297
  7. tight regulation of CCN3 expression is necessary for normal cortical neuronal connectivity during development, and RAB25 negatively regulates neuronal differentiation as a downstream effector of CCN3 PMID: 25871796
  8. CCN3 overexpression is associated with control of inflammatory processes and reversion of dyslipidemia in the process of atherosclerosis, which implies that CCN3 may be a promising target in the treatment of atherosclerosis. PMID: 24722330
  9. in obese humans and mice plasma NOV levels positively correlated with NOV expression in adipose tissue, and support a possible contribution of NOV to obesity-related inflammation. PMID: 23785511
  10. CCN3 is up-regulated in the early phase of bone regeneration and acts as a negative regulator for bone regeneration. PMID: 23653360
  11. CCN3 upregulates RANK expression in murine osteoclast precursors in RAW 264.7 cells to promote RANKL-dependent osteoclastogenesis. PMID: 23536580
  12. Expression of NOV and BNIP3 in leukemia AML-M(4) is significantly higher than that in normal controls. PMID: 21518474
  13. Nov stabilizes gremlin transcripts, and this effect is possibly mediated by AU-rich elements present in the 3'-UTR of gremlin. PMID: 21268093
  14. Ccn3/Nov is directly induced by cytokines through STAT5A/B. PMID: 20720003
  15. CCN3 counter-regulates positive signals from TGF-beta and Wnt for fibrillin fibrillogenesis and profibrotic gene expression. PMID: 20182440
  16. CCN3 suppresses neointimal thickening through the inhibition of vascular smooth cell migration and proliferation. PMID: 20139355
  17. Nov sensitizes osteoblasts to BMP-2, but Nov is dispensable for the maintenance of bone mass. PMID: 19934377
  18. CCN3 binds to the C terminus of Cx43 and has a role in mediating growth control induced by specific gap junction proteins PMID: 15213231
  19. Study indicates that NOV is a positive modulator of chondrogenesis. PMID: 16294274
  20. Taken together, these results identify NOV as an adhesion substrate for myoblasts which, in concert with growth factors, could play a role in the physiology of muscle cells. PMID: 16371345
  21. Results suggest that NOV (nephroblastoma overexpressed) is a specific cell fate regulator in the myogenic lineage, acting negatively on key myogenic genes thus controlling the transition from progenitor cells to myoblasts. PMID: 16600215
  22. Exerts inhibitory effects on bone morphogenetic protein-2(BMP-2)-induced osteoblast differentiation by its involvement of the BMP and Notch signaling pathways. PMID: 17250806
  23. Nov binds BMP-2 and antagonizes BMP-2 and Wnt activity, and its overexpression inhibits osteoblastogenesis and causes osteopenia. PMID: 17500060
  24. NOV is a regulator of skeletal and cardiac development, and implicates NOV in various disease processes including cardiomyopathy, muscle atrophy and cataract formation. PMID: 18289368
  25. CCN2 induces chondrocyte differentiation by regulating the expression of chondrocyte-associated genes but that these effects are counteracted by CCN3. PMID: 18597638

Show More

Hide All

Subcellular Location
Secreted. Cytoplasm. Cell junction, gap junction.
Protein Families
CCN family
Tissue Specificity
Expressed in large vessels including the ascending aorta, carotid arteries, and the thoracic aorta, in medium-sized vessels such as coronary arteries and small pulmonary veins and also in small vessels. In addition, also found to be present in the heart (
Database Links
CUSABIO guaranteed quality
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
7505 Fannin St., Ste 610, Room 322 (CUBIO Innovation Center), Houston, TX 77054, USA
Join Us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2023 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1